PURPOSE: Improvement in the cost-effectiveness of chemoprevention for prostate cancer could be realized through the identification of patients at higher risk. We estimated the cost-effectiveness of prostate cancer chemoprevention across risk groups defined by family history and number of risk alleles, and the cost-effectiveness of targeting chemoprevention to higher risk groups. MATERIALS AND METHODS: We developed a probabilistic Markov model to estimate costs, survival and quality adjusted survival across risk groups for patients receiving or not receiving chemoprevention with finasteride. The model uses data from national cancer registries, online sources and the medical literature. RESULTS: The incremental cost-effectiveness of 25 years of chemoprevention with finasteride in patients 50 years old was an estimated $89,300 per quality adjusted life-year (95% CI $58,800-$149,800), assuming finasteride decreased all grades of prostate cancer by 24.8%. Among patients with a positive family history (without genetic testing) chemoprevention provided 1 additional quality adjusted life-year at a cost of $64,200. Among patients with a negative family history at $400 per person tested, the cost-effectiveness of genetically targeted chemoprevention ranged from $98,100 per quality adjusted life-year when limiting finasteride to individuals with 14 or more risk alleles, to $103,200 per quality adjusted life-year when including those with 8 or more risk alleles. CONCLUSIONS: Although there are small differences in the cost-effectiveness of genetically targeted chemoprevention strategies in patients with a negative family history, genetic testing could reduce total expenditures if used to target chemoprevention for higher risk groups.
PURPOSE: Improvement in the cost-effectiveness of chemoprevention for prostate cancer could be realized through the identification of patients at higher risk. We estimated the cost-effectiveness of prostate cancer chemoprevention across risk groups defined by family history and number of risk alleles, and the cost-effectiveness of targeting chemoprevention to higher risk groups. MATERIALS AND METHODS: We developed a probabilistic Markov model to estimate costs, survival and quality adjusted survival across risk groups for patients receiving or not receiving chemoprevention with finasteride. The model uses data from national cancer registries, online sources and the medical literature. RESULTS: The incremental cost-effectiveness of 25 years of chemoprevention with finasteride in patients 50 years old was an estimated $89,300 per quality adjusted life-year (95% CI $58,800-$149,800), assuming finasteride decreased all grades of prostate cancer by 24.8%. Among patients with a positive family history (without genetic testing) chemoprevention provided 1 additional quality adjusted life-year at a cost of $64,200. Among patients with a negative family history at $400 per person tested, the cost-effectiveness of genetically targeted chemoprevention ranged from $98,100 per quality adjusted life-year when limiting finasteride to individuals with 14 or more risk alleles, to $103,200 per quality adjusted life-year when including those with 8 or more risk alleles. CONCLUSIONS: Although there are small differences in the cost-effectiveness of genetically targeted chemoprevention strategies in patients with a negative family history, genetic testing could reduce total expenditures if used to target chemoprevention for higher risk groups.
Authors: S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg Journal: N Engl J Med Date: 2008-01-16 Impact factor: 91.245
Authors: Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian L Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Paul A Fearn; Michael W Kattan Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: K Robin Yabroff; Elizabeth B Lamont; Angela Mariotto; Joan L Warren; Marie Topor; Angela Meekins; Martin L Brown Journal: J Natl Cancer Inst Date: 2008-04-29 Impact factor: 13.506
Authors: Rosalind A Eeles; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Michelle Guy; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angie Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jamieson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: John Hornberger; Mark Holodniy; Katherine Robertus; Michael Winnike; Erin Gibson; Eric Verhulst Journal: Med Decis Making Date: 2007 Nov-Dec Impact factor: 2.583
Authors: Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240